Research Analysts Issue Forecasts for ALDX Q3 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Research analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of Aldeyra Therapeutics in a report issued on Monday, August 17th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.08). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.16) EPS, FY2028 earnings at ($0.02) EPS and FY2029 earnings at $0.17 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09).

ALDX has been the topic of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aldeyra Therapeutics in a report on Monday. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Aldeyra Therapeutics currently has an average rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock opened at $1.55 on Wednesday. The stock has a fifty day moving average price of $1.80 and a 200 day moving average price of $2.53. The stock has a market cap of $93.51 million, a PE ratio of -3.97 and a beta of 1.22. Aldeyra Therapeutics has a 1 year low of $1.07 and a 1 year high of $6.17.

Insider Transactions at Aldeyra Therapeutics

In related news, CEO Todd C. Brady bought 250,000 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $1.67 per share, for a total transaction of $417,500.00. Following the acquisition, the chief executive officer owned 1,721,298 shares in the company, valued at $2,874,567.66. This represents a 16.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in shares of Aldeyra Therapeutics by 456.3% during the first quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock valued at $2,257,000 after acquiring an additional 321,992 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Aldeyra Therapeutics in the 1st quarter valued at about $218,000. Jane Street Group LLC purchased a new position in Aldeyra Therapeutics in the 1st quarter valued at about $1,024,000. Acadian Asset Management LLC lifted its holdings in Aldeyra Therapeutics by 7,402.7% in the 1st quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company’s stock valued at $551,000 after purchasing an additional 94,681 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after purchasing an additional 8,769 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.